secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001564590-22-018297
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M
------------------------------------------------------------------------------

- Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.
- Net loss $26.0M ($0.10 per share) vs $12.9M ($0.05) in Q1 2021, driven by lower collaboration revenue.
- Cash and investments $233.0M at March 31, 2022; Tyvaso DPI PDUFA action date expected May 2022.
- Collaborations & services revenue $2.2M, down $7.2M due to completion of R&D services for United Therapeutics.
- Deferred revenue from commercial supply agreement with United Therapeutics increased to $25.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/0001564590-22-018297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/mnkd-8k_20220505.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-018297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer